echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO: Phase 2 study of continuous talazopanib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer

    ASCO: Phase 2 study of continuous talazopanib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer

    • Last Update: 2022-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Talazopanib (TALA) inhibits cytotoxic effects by inhibiting poly ADP-ribose polymerase (PARP) proteins 1 and 2 and "trapping" PARP on D.


    Talazopanib (TALA) Talazopanib (TALA) Temozolomide (TMZ) Temozolomide ( TMZ) Second-Line Therapy for ES-SCLC

    Methods: This study is an open-label, single-arm, phase 2 study of the safety and efficacy of TALA plus TMZ in ES-SCLC patients refractory/relapsed to first-line platinum-based regime.


    TALA plus TMZ treatment

    The primary outcome measure was objective response rate (ORR) based on RECIST 1 criteria, 15% ORR for previous second-line topotecan as control, and 8 or more confirmed responses in 28 evaluable subjects (29% ORR) were achiev.


    Objective Response Rate (ORR)

    RESULTS: A total of 31 subjects were included, 3 of whom could not be assessed due to ineligibility or premature withdrawal of consent prior to the first disease assessme.


    Conclusion: The study exceeded its target response rat.


    Benefits of low-dose TMZ inhibition of PARP beyond its target response rate

     

    Original source:

    Jonathan.


    https://meetin.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.